Dr. Reddy’s Files Clean Secretarial Compliance Report for FY 2026
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On May 28, 2026, Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. SEC and notified the NSE, BSE, NYSE and NSE IFSC that it had submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026, as required under Regulation 24A of SEBI’s Listing Obligations and Disclosure Requirements. The report, issued by independent firm Makarand M. Joshi & Co., confirms that Dr. Reddy’s complied with applicable SEBI and listing regulations during the review period, notes no deviations or penalties, and indicates strong adherence to secretarial standards, governance policies and website disclosure norms, reinforcing its regulatory track record and governance credibility for shareholders and other stakeholders.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based multinational pharmaceutical company headquartered in Hyderabad, Telangana. It develops, manufactures and markets generic and branded formulations, active pharmaceutical ingredients and over-the-counter products, with listings on the NSE, BSE, NYSE and NSE IFSC, reflecting a diversified global investor base in healthcare and life sciences.
Average Trading Volume: 2,555,507
Technical Sentiment Signal: Buy
Current Market Cap: $11.55B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
